Hikma has struck a deal with Glenmark to gain US rights to the Indian firm’s investigational Ryaltris (olopatadine/mometasone) nasal spray. The agreement builds on what Hikma said was its “market-leading position in nasal allergy sprays.”
Glenmark will continue to develop the product and will be responsible for gaining US Food and Drug Administration approval, while Hikma will market Ryaltris and will also be able to produce the